Skip to main content
UHS logo

UHS · Universal Health Services Inc

Track UHS — free
$172.33 -0.76 (-0.44%) At close · Aug 19
Market Cap
$10.20B
Shares
58.94M

Price & Indicators

20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$172.33 Open$173.58 Day$172.33–179.30 52W close$141.17–244.18 Avg vol 30d895K Short int3.0M · 5.1% float · 2.6d Short vol59% Last earningsJul 28, 2026 DataJan 2020–Aug 2026 Filing10-Q · Aug 7

Up next

Next earnings call
Oct 27, 2026 Est · unconfirmed · in 10 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
filed Aug 7, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Neutral
      SellHoldBuy
      Technical Neutral Momentum Weak Sentiment Neutral Fundamentals Excellent Quant / Vol High
      Market backdrop VIX 14.9 · calm Equity put/call 0.52
      Technical
      price trend
      Neutral
      50 / 200-day cross No cross
      Price vs 200-day avg −9%
      below
      Price vs 50-day avg +10%
      above
      RSI (14) 61
      neutral
      MACD trend Negative
      52-week position 30%
      mid-range
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Weak
      1-month return +15%
      trailing
      6-month return −16%
      trailing
      YTD return −21%
      this year
      Relative strength −27%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) No cross
      50d $157 › 200d $189 — 200d above 50d
      Institutional flow Distributing
      -10% holders QoQ · +68 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      5.09% of float · ▼ -11.8% MoM · 2.6 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      591 holders — mid 3-yr range
      Squeeze score 58
      elevated · 0–100
      Fundamentals
      Excellent
      Revenue growth +10%
      Y/Y
      EPS growth +37%
      Y/Y
      Free cash flow $849.2M
      Valuation P/E 7.1
      below peers
      Buyback $977.6M
      remaining
      Balance sheet $4.6B
      net debt
      Quant / Vol
      risk profile
      High
      Volatility 32%
      annualized · 1-yr
      Max drawdown −42%
      past year
      ATR 3.3%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Latest guidance · from the Earnings Call filed Jun 30, 2026
      Same-facility acute care adjusted admissions growth · full year 1.5% – 2.5%
      Prior guidance period ended · from the 8-K filed Oct 28, 2025
      Net revenues · For the Year Ended December 31, 2025 $17.31B – $17.45B
      Adjusted EBITDA, net of NCI · For the Year Ended December 31, 2025 $2.57B – $2.62B
      Adjusted EPS – diluted · For the Year Ended December 31, 2025 $21.50 – $22.10
      Guided vs delivered · last 1 settled
      Net revenues For the Year Ended December 31, 2025
      guided $17.31B – $17.45B
      $17.36B In line

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Neutral
      2 · 4 · 1
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      −9% Bearish
      Price vs 50-day avg
      +10% Bullish
      RSI (14)
      61 Neutral
      MACD trend
      Negative Bearish
      52-week position
      30% Neutral
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Mixed
      Trend (MA cross) No cross
      50d $157 › 200d $189 — 200d above 50d
      Institutional flow Distributing
      -10% holders QoQ · +68 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      5.09% of float · ▼ -11.8% MoM · 2.6 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      591 holders — mid 3-yr range
      Price context
      position in its 52-week range
      Range low $141 Now $172 · 30% Range high $244
      vs 200-day avg -9% vs 50-day avg +10%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from written earnings releases and filings
      Metric Latest Period YoY
      Adjusted admissions (acute care, same facility basis) 1.4% first six months of 2026
      Days Sales Outstanding 56 Six months ended 6/30/2026
      Debt / Adjusted EBITDA net of NCI non-GAAP 1.81 Six months ended 6/30/2026
      Debt / Cash From Operations 2.7 Six months ended 6/30/2026
      Debt / EBITDA net of NCI 1.73 Six months ended 6/30/2026
      Debt / Total Capitalization 39.2% Six months ended 6/30/2026

      Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

      Versus peers

      Medical Care Facilities — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      UHS
      Universal Health Services Inc
      this stock
      $10.20B -21.0% +9.7% 7.1 5.1%
      HCA
      HCA Healthcare, Inc.
      $90.30B -12.8% +7.1% 14.0 2.7%
      FSNUY
      Fresenius SE & Co. KGaA
      $30.84B -4.5% 0.0%
      THC
      Tenet Healthcare Corp
      $21.76B +35.1% +0.9% 10.4 4.0%
      FMS
      Fresenius Medical Care AG
      $12.69B +0.1% +5.9% 0.5%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      591
      % held
      89.1%
      Net QoQ
      +942.8K sh
      Top holder
      First Eagle Investment Ma…
      Held Float
      View
      Held by Funds
      Fund positions
      663
      View
      Short & Settlement
      Short Interest Falling
      Shares short
      3.0M
      Days to cover
      2.6d
      Change
      -401.2K sh
      View
      Short Volume
      Short vol %
      59%
      As of
      Aug 19, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      4
      Value
      $653
      As of
      Jul 31, 2026
      View
      Off-Exchange
      Off-exchange %
      45.8%
      Week of
      Jul 13, 2026
      Off-exch Lit
      View
      Smart Money
      Congressional Trades Buy
      Member
      Alan Armstrong
      Amount
      $1.0K–$15.0K
      Traded
      Mar 27, 2026
      View
      Financials
      Financials
      Revenue (FY)
      $17.4B
      Net income (FY)
      $1.5B
      EPS diluted
      $23.10
      View
      Buybacks
      Authorized · 3 programs
      $5.0B
      Remaining
      $977.6M
      Spent Remaining
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Aug 17, 2026
      This year
      16
      View
      Proposed Sales
      Value
      $68.8K
      Shares
      356
      Filed
      Mar 13, 2026
      View
      Earnings & Events
      Earnings Calls
      Last call
      Jul 28, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      UHS -0.1% +15.4% -15.7% +2.3% -21.0%
      SPY -0.4% +2.9% +11.6% +3.0% +12.8%
      vs SPY +0.4% +12.5% -27.2% -0.6% -33.7%

      Capital returns

      Latest dividend
      $0.20 / share · ex Jun 8, 2026
      Declared · upcoming
      $0.20 / share · ex Sep 1, 2026
      Paid (TTM)
      $0.80 / share · 4 payouts
      Dividend yield (TTM, derived)
      0.46%
      Buyback programs · 3 active · as of Jun 30, 2026
      Authorized (total)
      $5.00B
      Spent (derived)
      $4.02B
      Remaining
      $977.60M
      Spent Remaining

      Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

      Key facts CIK 352915 CUSIP 913903100 13F (30d) 540 filings 522 filers Visit website Investor relations